Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(D405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-Å resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The DF508 version of this protein also crystallizes as a homodimer and differs from the wildtype structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.
Introduction
Cystic fibrosis affects $30 000 individuals in the USA and is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR; http://www.cff.org/AboutCF/Faqs/; Riordan et al., 1989) . Although over a thousand diseasecausing CFTR mutations have been described, most patients harbor a deletion of phenylalanine 508 (DF508) in at least one CFTR allele (http://www.genet.sickkids.on.ca/cftr/). Vastly improved through the management of infection and nutrition, the life expectancy of those born with two defective CFTR genes is 36.9 years (Cystic Fibrosis Foundation, 2006) .
CFTR is a member of the ATP-binding cassette (ABC) transporter family of proteins, a very large family responsible for ATP-coupled, transmembrane transport of a diverse array of molecules (Holland et al., 2003; Oswald et al., 2006; Linton and Higgins, 2007) . The core architecture of ABC transporters consists of two transmembrane domains (TMDs), which together form the solute pore, and two nucleotide binding domains (NBDs), which regulate transport through the pore. A defining feature of the family is the presence of a conserved LSGGQ sequence motif within the NBDs. Structural and functional evidence indicates that membrane transport requires association of the NBDs as a head-to-tail dimer, sandwiching ATP molecules between the consensus Walker A and the signature LSGGQ motifs in two composite ATP sites (Gadsby et al., 2006; Oswald et al., 2006) . CFTR contains two TMDs and two NBDs (NBD1 and NBD2) within a single polypeptide chain. The NBD2 Walker A region and the NBD1 LSGGQ motif of CFTR form a composite ATP binding site that supports nucleotide hydrolysis, whereas juxtaposition of the NBD1 Walker A region and the NBD2 signature motif supports binding but not nucleotide hydrolysis (Aleksandrov et al., 2002) .
CFTR is unique among ABC transporters in being a simple ion channel rather than an active transporter (Sheppard and Welsh, 1999; Hanrahan et al., 2003; Holland et al., 2003; Gadsby et al., 2006) . It also contains a 200 amino acid regulatory (R) domain between the two TMD -NBD cassettes and a non-canonical 30 residue insertion near the N-terminus of NBD1 (Lewis et al., 2004) . This 30 residue insert as well as a 30 residue extension of NBD1 were identified in the initial high-resolution structures as regions atypical for NBDs and containing sites of in vitro PKA phosphorylation. The former was termed the regulatory insert (RI) and the latter the regulatory extension (RE) (Lewis et al., 2004) .
Eubacterial and archael ABC transporters consist of various arrangements of TMDs and NBDs, mostly as separate polypeptides (Holland et al., 2003) . In higher organisms, single-chain ABC transporters that lack strict 2-fold symmetry, such as CFTR, are more common. The experimental challenges posed by these systems are further increased in CFTR by the presence of regulatory regions. At present, there are no published high-resolution structures of full-length CFTR or any other single-chain ABC transporter. The recently published 3.8 Å P-glycoprotein structure is the first moderate-resolution structure of a heterodimeric ABC transporter (Aller et al., 2009) . Detailed (i.e. ,3.0 Å resolution) structural knowledge of CFTR is only available for NBD1 (Lewis et al., 2004 (Lewis et al., , 2005 Thibodeau et al., 2005) . Our understanding of the structure of full-length CFTR is largely inferred from structures of symmetric eubacterial and archael ABC transporters (Dawson and Locher, 2006; Hollenstein et al., 2007; Hvorup et al., 2007; Locher et al., 2002; Oldham et al., 2007; Pinkett et al., 2007; Ward et al., 2007) and lowresolution electron microscopic studies of murine CFTR (Rosenberg et al., 2004) . The most closely related homodimeric ABC transporter structure is that of Sav1866 from Staphylococcus aureus (Dawson and Locher, 2006) . Its TMDs have the same number of helices as CFTR and, like CFTR, contain a significant inner membrane portion.
The study of individual CFTR domains has yielded insights into both structure and function, but has been hampered by the low solubility of isolated CFTR domains. We describe herein a new approach to NBD1 production and purification which relies on removal of the RI (Atwell et al., 2007; Cheung et al., 2008) . The resulting proteins are wellbehaved in solution and crystallize readily, yielding X-ray structures of wild-type and DF508 NBD1 as head-to-tail homodimers at 1.7 and 2.0 Å , respectively. In addition, we report the structure of a slightly longer version, which yields a monomeric structure at 1.8 Å resolution. Together, these structures provide high-resolution views of NBD1 in its unassociated state, as a dimer and as a pathogenic DF508 mutant, in the absence of solubilizing mutations.
Materials and methods

Cloning and solubility testing
Human CFTR NBD1 was amplified from a full-length wildtype CFTR clone by the polymerase chain reaction (PCR) using the forward primer 5 0 -ACGACTACAGAAGTAGTGA TGGAGAATGTAACAGCCTTCTGGGAGGAGGGAGGTA CTCCTGTCCTGAAAGATATTAATT-3 0 and the reverse primer 5 0 -TTATCATCCCATGAGTTTTGAGCTAAAGTC-3 0 (Integrated DNA Technologies, Skokie, IL, USA). The resulting product was cloned into a TOPO adapted (Invitrogen, Carlsbad, CA, USA) pET26b-derived expression vector, which fuses the expressed polypeptide to an MGSSH 6 _Smt3_SL tag (Lewis et al., 2004) . After cleavage of the tag, the resulting protein is ] (2935c469). The N-terminal cloning artifact serine is present in all of the constructs, though not always indicated in the descriptions. N-terminal extensions and C-terminal truncations of this construct were prepared by PCR amplification from this clone and subcloned into the same expression vector. The DF508 mutant (2935c472) was prepared by QuickChange mutagenesis of 2935c469 according to the manufacturer's protocol (Stratagene, La Jolla, CA, USA). All variants were confirmed by DNA sequencing (Bio Applied Technologies Joint, San Diego, CA, USA) (Table I) . Medium-scale solubility tests were performed by growing 50 ml expression cultures. After lysis by sonication, proteins from the soluble fraction of the lysates were purified using Ni-NTA agarose resin (Qiagen, Valencia, CA, USA) in a gravity flow apparatus. Eluted protein was analyzed before or after proteolytic cleavage of the Smt tag by Ulp1 (using a 100-fold dilution of 1 mg/ml Ulp1) by passage through 100 or 300 kDa spin filters (Pall Life Sciences, Ann Arbor, MI, USA) followed by SDS-PAGE.
Purification
Large-scale protein purification was conducted as described previously (Lewis et al., 2005) , yielding protein in the following buffer: 150 mM NaCl, 10 mM methionine, 10 mM HEPES pH 7.5, 10% glycerol, 1 mM tris(2-carboxymethyl)phosphine (TCEP), 2 mM ATP. Proteins were .98% pure, showed no evidence of aggregation and ran as monomers during gel filtration. Methionine was included to protect against potential oxidation. All variants were characterized by analytical gel filtration using an Agilent 1100 HPLC and a 4.6 Â 250 mm column (Agilent, Wilmington, DE, USA) in the purification buffer.
Protein characterization
Protein stability experiments were conducted by thawing frozen protein, diluting to 2 mg/ml with storage buffer, adding Smt3 protein to a final concentration of 1 mg/ml as a reference, buffer exchanging into 10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP with or without 10% glycerol using a G25 MiniSpin column (The Nest Group, Southborough, MA, USA), and incubating the protein for 3 days at 48C. An aliquot of protein was then taken, insoluble material removed by centrifugation and passage through a 300-kDa spin filter (Pall Life Sciences, East Hills, NY, USA). Samples taken before and after removal of insoluble protein were analyzed by SDS-PAGE.
Measures of temperature induced protein unfolding were conducted by differential scanning calorimetry (DSC) on a Nano-DSC in 0.299 ml cells at a heating rate of 18K/min. An external pressure of 2.0 atm was maintained during all DSC runs to prevent possible degassing of the solutions on heating. Protein concentrations were 78 mM in 20 mM HEPES buffer pH 7.5, 150 mM NaCl, 10% glycerol, 10% ethylene glycol, 5 mM ATP, 10 mM MgCl 2 , 1 mM TCEP. DSC data were analyzed with the MicroCal Origin software.
Nucleotide-binding kinetic data were obtained by surface plasmon resonance (SPR) on a Biacore T100 with a researchgrade CM5 sensor chip (GE Healthcare, Piscataway, NJ, USA). After the sensor surface was activated using the amine coupling kit (GE Healthcare), streptavidin (Pierce, b 2935c382 is hNBD1-3 from Lewis et al. (2005) . c 2935c371 is hNBD1-3 with the DF508 mutation.
Rockford, IL, USA) was immobilized to the surface. Coupling reactions were conducted at 328C. Subsequent reactions and experiments were conducted at 48C. Proteins 2935c469, 2935c382 and a non-ATP-binding protein were biotinylated using NHS-biotin (Pierce) for 1 h and desalted into 10 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 3 mM MgCl 2 , 1 mM ATP and 1 mM DTT using a Superdex 200 gel filtration column. The proteins were then captured by the streptavidin surface in different flow cells with final densities of 5000 -6000 response units. A 3-fold dilution series of nucleotides (starting from 55.6 mM for ATP, ADP, AMP-PNP and AMP; and 3.7 mM for N6-PhEt-ATP) in 10 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 3 mM MgCl 2 and 1 mM DTT was injected through the sensor chips yielding data for five different nucleotide concentrations. Binding sensograms were analyzed and fit globally with Scrubber 2 software (BioLogic Software Pty Ltd, Campbell, Australia) using a 1:1 interaction model with mass transport parameters. Kinetic data were extracted from duplicate experiments and averaged (Table II) .
Crystallization
Purified proteins were screened for crystallization at 9 -11 mg/ml by sitting drop vapor diffusion (1 ml protein added to 1 ml well solution) using five 96-well screens at 88C and 218C (Classics, Classics II, PEGs, PEGs II and ComPAS; Qiagen). Crystallization conditions are provided in Table III . Crystals from the initial screens or optimization experiments were harvested by transferring to a solution containing the components of the crystallization well solution plus 25% (v/ v) dimethyl sulfoxide (DMSO) or 25% (v/v) glycerol and then frozen by rapid immersion in liquid nitrogen. Diffraction data were recorded under standard cryogenic conditions using the SGX-CAT beamline 31-ID at the Advanced Photon Source using a MAR detector and processed with Mosflm (CCP4, 1994) .
Structure determination
A molecular replacement solution was determined for 2935c469 using a published structure of NBD1 (PDB code 1XMI) with molrep from the CCP4 crystallographic software suite (CCP4, 1994) . Multiple cycles of fitting using Xfit (McRee, 1999) with SigmaA weighted maps and maximumlikelihood minimization using Refmac 5 (CCP4, 1994) were performed. Structures of 2935c472 and 2935c492 were determined by molecular replacement using 2935c469 as a starting model and refined using a similar strategy. See Table III for data collection, refinement statistics and PDB accession codes.
Buried surface area calculations were conducted using the protein interfaces, surfaces and assemblies service (PISA) at European Bioinformatics Institute (http://www.ebi.ac.uk/ msd-srv/prot_int/pistart.html). Structural comparisons of human NBD1s were conducted using the align feature of Pymol (DeLano, 2002) with a minimal set of diverse monomers selected from all available NBD1 monomers: 1XMIC (PDB code 1XMI, chain C), 1XMID, 1XMJA, 2BBOA, 2BBSA, 2BBTB, 1R0ZA, 1R0ZD, 1R10B. Similar comparisons were performed with NBD head-to-tail homodimers from other ABC transporters (PDB codes 2IXE , 
Data deposition
Atomic coordinates and structure factors have been deposited in the Protein Data Bank (http://www.rcsb.org/pdb). Accession codes are listed in Table III .
Results
Elimination of human NBD1 elements able to interfere with native-like association with other CFTR domains
The initial goal of this study was to produce a form of NBD1 suitable for study of its association with isolated NBD2 and with other CFTR domains. Examination of NBD1 structures and their alignment with the recently published structure of the Sav1866 ABC transporter (Dawson and Locher, 2006) suggested three modifications of the existing constructs.
C-terminal truncation. Since the RE as it is observed in NBD1 structures would obstruct head-to-tail dimer formation, the C-terminus was truncated at residue 646. This is the last residue that would not interfere with dimer formation in any of the observed conformations.
RI removal. The RI might interfere with interdomain interactions in three ways. Some of its observed conformations would prevent head-to-tail dimer formation. Its hydrophobic residues may reduce aqueous solubility. Its participation in intermolecular crystal contacts with the Q-loop cleft in several crystal forms may prevent native interactions of NBD1 with TMDs (see, e.g. PDB codes 1R0Z and 2BBT). The RI, specifically residues 405 -436, was therefore removed, fusing residue 404 to 437.
Native sequence. The native amino acid sequence of NBD1 was retained to ensure native interactions with NBD2 and the TMDs. The new constructs described here do not contain any of the previously reported mutations that increased the solubility of NBD1 (Lewis et al., 2005) .
The behavior of NBD1 387 -646(D405 -436) (2935c469) and closely related constructs is described below. This construct and its variants will be described as 'truncated NBD1', referring to the truncation of the RI and RE.
NBD1 387-646(D405-436) migrates as a monomer during gel filtration and is more soluble than non-truncated NBD1 2935c469 and its variants behave as monomers during analytical ( Fig. 1 ) and preparative gel filtration chromatography, showing no evidence of dimerization. In small-and medium-scale solubility tests, the 2935c469 protein appeared to be more soluble. Large-scale purification demonstrated an absence of the void volume aggregates typical of earlier NBD1 constructs and no visible precipitation between purification steps or after a freeze-thaw cycle was observed (not shown).
In an attempt to quantify this improved solution behavior, we incubated several purified forms of human NBD1 at 48C for 3 days and then determined the extent of insoluble material formed by running SDS -PAGE on each sample before and after filtration. In the absence of glycerol, 90% of truncated NBD1 remains soluble ( Fig. 2A, lanes 1 and 2) , whereas only 60% of a non-truncated NBD1 remains soluble (Fig. 2B, lanes 1 and 2) . For either truncated or nontruncated DF508, solutions lacking glycerol resulted in loss of the majority of the protein from the soluble fraction. However, in the presence of glycerol, 80% of DF508 truncated NBD1 remains in the soluble fraction ( Fig. 2A, lane  8) , whereas only 10% of the non-truncated version does (Fig. 2B, lane 8) . Thus, the solubility of both native and DF508 NBD1 is improved considerably by the truncation.
Human NBD1 387-646(D405-436) is more stable and binds ATP tighter than non-truncated constructs Truncated and non-truncated NBD1 proteins were analyzed for their thermal unfolding properties: NBD1 387-646(D405-436) and NBD1 389 -678[F429S,F494N,Q637R] . Truncated NBD1 with native sequence is 7.78C more stable than the non-truncated NBD1 with solubilizing mutants (Fig. 3) . From the difference in calorimetric and van't Hoff enthalpies as well as non-uniformity in the melting curve, aggregation appears to play a role in the measured T m s and this role is being investigated.
Truncated and non-truncated NBD1 proteins were also analyzed for their nucleotide-binding affinities using SPR on a Biacore instrument (Table II; Rich and Myszka, 2005) . Relative to the non-truncated NBD1, the truncated NBD1 showed higher affinity for all the nucleotides that bound. There was a modest 3 -4-fold improvement for ATP and AMP-PNP and a more dramatic 16-fold improvement for ADP and 10-fold for N6-PhEt-ATP. AMP showed no detectable binding to either protein.
Human NBD1 387-646(D405-436) crystallizes as a head-to-tail homodimer 2935c469 crystallizes readily in various conditions containing medium molecular weight PEGs, e.g. 25% PEG 6 K/100 mM HEPES pH 7.5. The resulting 1.7 Å resolution structure contains two copies of the human CFTR NBD1 domain interacting as a head-to-tail homodimer (Table III and Fig. 4 ). Both monomers have the typical ABC transporter NBD fold, which contains a mostly b-sheet, RecA-like subdomain, including the Walker A and Walker B motifs, and a mostly a-helical subdomain, including the ABC family signature LSGGQ (C-loop) motif. The room-mean-square deviation (rmsd) between molecule A and the A molecule of 1XMI is 0.5 Å for 204 Ca atomic pairs.
The deletion of the 31 residue RI does not appear to have disrupted the NBD structure. Deletion of residues 405 -436 connects the first and second b-strands of NBD1, yielding a (2935c469) and without F508 (2935c472) as well as non-truncated NBD1 (2935c382) in 150 mM NaCl, 10 mM methionine, 10 mM HEPES pH 7.5, 10% glycerol, 1 mM TCEP, 2 mM ATP was analyzed using an Agilent 1100 HPLC instrument with a size-exclusion column (ZORBAX GF-250). A calibration mixture of bovine serum albumin (BSA, MW 66.6 kDa) and carbonic anhydrase (MW 29.0 kDa) was used to obtain reference retention times. Fig. 2 . Solubility of NBD1 constructs. Proteins were incubated in 10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP with or without 10% glycerol for 3 days at 48C, aliquots taken and insoluble material removed by centrifugation followed by filtration with a 300 kDa cut-off. Samples prepared from before and after removing insoluble material and aggregates were analyzed by SDS-PAGE. Samples were run in pairs of unfiltered (lanes 1, 3, 5, 7 '2' 300 kDa filter) and filtered (lanes 2, 4, 6, 8 'þ' 300 kDa filter). Two buffers were tested, one without (lanes 1, 2, 5, 6 '2' 10% glycerol) and one with 10% glycerol (lanes 3, 4, 7, 8 'þ' 10% glycerol). type I turn similar to some NBDs lacking such inserts (e.g. 2HYD and 1XEF). Superposition of this portion of the structure with the corresponding region in previously published NBD1 structures reveals no significant differences in the b-strands connected by the new loop (Trp410 Ca -Ca ¼ 0.5 Å , Pro439 Ca -Ca ¼ 0.2 Å in an alignment with 1XMJ). Removal of the ordered RE yields only a modest difference at the C-terminus of human NBD1. The C-terminal region in the homodimer structure is invariant up to the helix-breaking residue Pro638. The final two-turn a-helix is only ordered in one molecule of the head-to-tail dimer and differs from that seen in previous structures. The ordered C-terminus in molecule A ends near the dimer-related B molecule. The orientation of this a-helix is highly variable among NBD1 structures, even among different protomeric copies in the same crystallographic asymmetric unit (e.g. 1XMI chain A versus chain B, Lewis et al., 2005) .
Bound ATP molecules are sandwiched between the Walker A motif at the beginning of Helix 1 of one monomer and the signature LSGGQ motif at the beginning of Helix 5 of the other monomer ( Fig. 5 ; secondary structural elements designations according to Lewis et al., 2004) . Among other interactions, this mode of interaction with ATP aligns the b phosphate with the positive dipole moment of the Walker A a-helix and the g phosphate with the positive dipole moment of the signature helix. Assuming that ATP.Mg 2þ is pre-bound at the primary ATP half-sites, the formation of the homodimer buries 2367 Å 2 solvent-accessible surface area. This is slightly more than the 2200 Å 2 buried in the native homodimer of the mj0796 NBD (1100 Å 2 per protomer; Smith et al., 2002) . Standard protein -protein complexes bury 1600 + 400 Å 2 putting these NBD dimers at the upper limit of standard complexes and the lower limit of large interfaces (Janin et al., 2007) .
Interactions of NBD1 with ATP.Mg 2þ at the primary halfsite resemble those seen in earlier published structures of human CFTR NBD1. Trp401 stacks against the adenine base, Walker A residues coordinate the phosphates, and the Q-loop Gln493 coordinates the g phosphate. Like previous CFTR NBD1 structures, Gln493 is positioned closer to ATP than in other NBD structures and coordinates both the g phosphate and bound Mg 2þ (Gln493 O11-Mg ¼ 2.25 Å ). This position contrasts with the position of the equivalent Gln90 in mj0796 which is thought to participate in the attack of a hydrolytic water (Smith et al., 2002) . The 'switch' residue, normally a histidine in catalytically active NBD halfsites, is Ser605 in this inactive NBD half-site. Not only is it unable to participate in catalysis in the manner of a histidine, but it is also retracted from the dimer interface along with helix 7 by $4 Å (switch residue Ca to Ca distance in an alignment with PDB code 1L2T).
This structure shows how ATP occupies the signature LSGGQ half-site in NBD1 (Fig. 5) . Ser549 packs against the a phosphate. The backbone amides of Gly550 and Gly551, at the N-terminus of Helix 5, coordinate the g phosphate. Gln552 completes the first turn of Helix 5, packing against the first signature residue, Leu548, and making hydrogen bonds with both the 2 0 and 3 0 ribose hydroxyls (Gln552B O11 -ATP1 O2' ¼ 2.7 Å , Gln552B N12 -ATP1 O3' ¼ 3.0 Å ). The backbone of Thr547 (the residue immediately preceding the signature motif ) packs against the adenine base. This residue would be considered part of the signature motif, except that its interactions with ATP involve backbone and Cb atoms. As a consequence, no sequence conservation among NBDs exists to highlight its importance, though this interaction is evident in all published head-to-tail NBD homodimer structures.
Comparing the homodimer structure with other structures of human NBD1 reveals that interactions at the primary ATP half-site are preserved. In the secondary half-site, the conformation of the signature LSGGQ residues is conserved as well, indicating that the signature residues are preformed for ATP binding in the monomeric NBD1 structures. Fig. 3 . DSC unfolding of NBD1 constructs; 800 ml of each protein at 78 mM in 20 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 10% ethylene glycol, 5 mM ATP, 10 mM MgCl 2 , 1 mM TCEP was loaded into the DSC cell. Shown are excess Cp profiles after baseline subtraction. a Binding parameters were determined by globally fitting nucleotide association and dissociation sensograms at five concentrations of nucleotide to a mass transport limited 1:1 interaction model (Fig. S1 , Supplementary data are available at PEDS online). Parameters from two identical experiments were averaged. b AMP was similarly tested and showed no detectable binding to either protein.
c Number in brackets indicates the standard error in the last significant digit from duplicate measurements.
In contrast, the conformation of residues 542 -547 immediately preceding the signature motif (the 'presignature loop') differs dramatically on ATP binding (Fig. 6 ). In the homodimer structure, this loop adopts a tight turn with a backbone hydrogen bond between the carbonyl of Gly542 and the amide of Gly545 (O -N distance ¼ 2.9 and 3.2 Å in the A and B molecules, respectively). This orients the side chains of residues Glu543 and Ile546 toward solvent, which positions them for possible interactions with the intracellular loops (ICLs) of the TMDs. This presignature loop conformation appears to be stabilized by the packing of Thr547 against the adenine base. In previously published human NBD1 structures, this loop is either disordered or adopts a conformation different from that observed in the homodimer.
In most of these previously published monomeric NBD1 structures, the side chain of Thr547 would interfere with ATP binding. So, while the signature residues are preformed for ATP binding, Thr547 and the presignature loop are not. The loop conformation observed in the homodimer is also observed in mouse NBD1s that form crystal packing interactions with Thr547 (e.g. PDB code 1R0Z), as well as the structure of the Sav1866 homodimer, in which there are several inter-monomer interactions between this loop and the ICLs (PDB code 2HYD). The carboxylate and carbonyl oxygen atoms of Sav1866 Glu473 (equivalent to Glu543 of NBD1) form hydrogen bonds with the amide and carbonyl of Val117 and Ala113 of ICL1 (3.0 and 3.3 Å , respectively).
Besides the nucleotide-mediated dimer interactions, there are protein:protein interactions in the homodimer at and around the D-loop. Gly576 and Tyr577 of the D-loop enclose the 2-fold axis with the side chains of symmetry-related Tyr577 residues stacking next to one another. The geometry of this side chain is far from ideal (x 2 ¼ 2168 and 2268; ideal ¼ 2658; Lovell et al., 2000) and the density poor. It is easy to imagine that the histidine in the equivalent position in NBD2 (His1375) would relieve the crowding in the homodimeric interaction. A hydrogen bond forms between Arg555 and Thr460 (Nh1-Og 3.2 and 3.4 Å ), an interaction equivalent to the Arg555/Thr1246 interaction demonstrated between NBD1 and NBD2 in CFTR channels (Vergani et al., 2005) since the threonine is conserved in both NBD1 and NBD2.
Deletion of Phe508 alters local structure
The DF508 variant of the 387 -646(D405-436) construct (2935c472) yields crystals in the same crystal form as the parent construct, with the same space group and similar cell parameters. The resulting 2.0 Å structure can therefore be used to assess the effects of the DF508 mutation in the context of truncated but otherwise wild-type NBD1. A similar analysis has been conducted comparing a human DF508 NBD1 with a human F508A NBD1 with different sets of solubilizing mutations (Lewis et al., 2005) . A more recent comparison utilizes structures with the same set of solubilizing mutations (H. Lewis personal communication) .
In the deletion mutants, the side chain of Phe508 is no longer present in the Q-loop cleft, probably the most important consequence of the pathogenic mutation (Fig. 7) . The positions of Ile507 and Ser511 are unchanged. The intervening Gly509-Val510 dipeptide adopts a different conformation in the truncated and non-truncated DF508 structures. Val510, which is partially buried in the non-deletion structures, is exposed to solvent in the deletion mutants (Fig. 7) . The shift of Val510 is less in the truncated structures with and without DF508 (Ca -Ca ¼ 3.0 Å ) than in the non-truncated structures (Ca -Ca ¼ 4.0 Å ). Interestingly, mutations of Val510 to several residues including Asp have been shown to rescue the processing of DF508 CFTR (Wang et al., 2007) . Trp496 makes a van der Waals contact with Phe508 in the nondeletion structures, but rotates toward the dimer interface in the truncated DF508 structure. This movement of Trp496, evident only in the homodimer DF508 structure, could contribute to a loss of native NBD1 interactions with the TMDs in DF508 CFTR.
Lengthening the N-terminus yields a monomeric structure Seventeen variants of NBD1 387 -646(D405 -436), all lacking the RI, were prepared with different N-termini (starting at residues 364, 372, 375, 378, 381, 383 and 390) or C-termini (terminating at each residue between 636 and 645). In medium-scale solubility studies, the solubility was unchanged among proteins ending between 640 and 645, shorter proteins showed significant reductions in solubility (,50% of 2935c469). N-terminal extensions were well tolerated to approximately Gln372. One variant with a longer N-terminus, NBD1 375-646(D405 -436) (2935c492), was . The effect of the DF508 mutation; 387-646(D405-436) (2935c469, dark green) and DF508 version (2935c472, lime green) show local changes to the F508 loop and a shift of Trp496 side chain. The 389-678(F409L, F429S, F433L, G550E, R553Q, R555K, H667R) (hNBD1-7a) structures are shown without (dark blue) and with the DF508 mutation (light blue) (H. Lewis, in preparation). purified to homogeneity and crystallized, yielding a lowresolution (3.0 Å ) homodimeric structure as well as a 1.8-Å resolution structure in a different crystal packing arrangement. In this latter structure, the asymmetric unit contains two monomers of NBD1 not associated as a head-to-tail dimer. Protomer contacts in this crystal are crystal lattice contacts (,550 Å 2 of buried surface area). Comparing this monomeric structure of NBD1 375-646 (D405 -436) with the structures of homodimeric wild-type and DF508 NBD1 reveals a few differences. In the B molecule, which does not form crystal contacts in the presignature region, the presignature loop is disordered (Fig. 6) confirming the mobility of this loop in the non-ATP-bound state of NBD1. The aromatic side chains at the face of the monomer involved in dimerization (residues Phe494, Tyr577) are in slightly different conformations than seen in the homodimer structures. The density for Tyr577 in particular is improved and its conformation more typical for tyrosine residues (Lovell et al., 2000) . Residues 494 -497 are better ordered, with lower B factors and better density than in the dimer structures. These observations indicate that the non-native NBD1:NBD1 interactions in this central region of the homodimer structure are probably destabilizing. Though this protein has 13 additional residues at the N-terminus, the ordered residues in the structure do not extend beyond residue 387.
With regard to the definition of NBD1, we suggest that the NBD1 domain encompasses residues Glu391 to Pro638 (the first and the last invariant residues among the available structures) excluding residues 405 -436. Additional residues at the N-and C-terminus improve behavior of the isolated domain and the 387 -646(D405 -436) construct described here is a nearly ideal minimal NBD1 for biophysical studies. The RI and RE are not required to form stable, ordered, ATP-bound NBD1.
Discussion
The initial goal of these experiments was to obtain soluble NBD1 protein appropriate for forming complexes with other domains of CFTR. NBD1 387 -646(D405-436) eliminates the elements of previous NBD1 constructs that might interfere with NBD2 or TMD interactions, namely the RI, RE and solubilizing mutations. This truncated NBD1 protein is highly soluble and well-behaved.
The published observation that only constructs retaining the RE are soluble (Lewis et al., 2004) and the fact that solubilizing mutations improve the solubility of non-truncated (Lewis et al., 2005) and truncated NBD1 (not shown) together imply that removing the RI is the major cause of the improved behavior of truncated NBD1. The beneficial effects of removing the RI are significant enough to counteract the absence of the RE and solubilizing mutations. Similar solubility improvements have been observed with D405-434 constructs (H. Lewis, unpublished results) .
A mechanism by which the RI could decrease solubility is suggested by the crystal packing interactions of the published NBD1 structures. In these structures, an ordered portion of the RI sometimes forms crystal packing interactions with the Q-loop cleft of neighboring molecules (e.g. PDB code 1R0Z). This type of interaction could contribute to aggregation of the non-truncated NBD1s. Many of the solubilizing mutations developed for non-truncated NBD1 are in the RI or Q-loop cleft (F409L, F429S, F433L and F494N) and might function by reducing these interactions. It is also possible that the RE contributes to solubility by blocking additional RI-binding sites. By removing the RI, the truncated NBD1s have improved solubility and do not require the RE or solubilizing mutations. The published structures also indicate how the RI might reduce nucleotide affinity, by transiently adopting conformations that would interfere with nucleotide binding or dramatically change its character (e.g. PDB code 1R0Z).
If the RI reduces NBD1 stability, solubility and nucleotide binding, what is its role in full-length CFTR? Reconstitution of split-channel CFTR originally indicated that NBD1 started at residue 433 (Chan et al., 2000) . It was not until the determination of the mouse NBD1 crystal structure that the insert was identified between the first and second b-strands of the NBD, showing that NBD1 actually starts around residue 389 (Lewis et al., 2004) . This was later confirmed by the various structures of human NBD1 with different sets of solubilizing mutations.
In the first description of the NBD1 structure, the insert was termed the 'RI' because it includes a site of in vitro PKA phosphorylation, Ser422. This characterization was later challenged (Csanady et al., 2005) . The experimental basis of this challenge was recordings of a split channel missing residues 415-432, which removes Ser422, but not the most hydrophobic portions of the RI. The fact that removing Ser422 has a minimal effect on regulation does not, however, show that it is not a regulatory site. None of the individual phosphorylation sites in CFTR have been shown to be critical for regulation but phosphorylation in aggregate is (Sheppard and Welsh, 1999) . Phosphorylation of Ser422 could play an incremental role in the domain associations, dissociations or conformational changes that activate CFTR just as the other sites of phosphorylation do. For simplicity, we continue to refer to this region as the 'RI', but its actual role remains to be elucidated.
A review of the various available crystal structures does at least indicate what the insert is not. It is partially ordered in many of the structures but does not interact in a consistent manner with the remainder of NBD1. It frequently participates in crystal contacts. This observation and the fact that removing the insert stabilizes NBD1 and increases ATP affinity argue that the insert has not evolved as an added element of the NBD1 domain in CFTR. It is largely helical when ordered and the ordered region contains a large number of exposed hydrophobic residues that do not interact with one another to form a mini-hydrophobic core (see, e.g. 1R0Z and 1XMI). We suggest that the RI forms a small helical subdomain that stably interacts with another domain in CFTR or another protein in the CFTR complex (Guggino and Stanton, 2006; Ollero et al., 2006) . In CFTR, the most obvious candidates are NBD2 or the ICLs. Sampling of potential RI positions (by rigid rotation of the helices) in an alignment with the Sav1866 structure suggests that the helical subdomain of NBD2 is probably too far away to interact with the hydrophobic residues of the RI. However, in models of CFTR, the ICL1 and the end of transmembrane helix 6 (the linker between TMD1 and NBD1) are positioned to interact with this region of the RI. This hypothesized interaction between the RI and ICL1 is supported by the observation that ICL1 peptides can capture non-truncated NBD1 in pull-down assays (E. Sorscher, personal communication). It is also possible that the RI interacts with other domains or plays a more dynamic role, forming transient interactions with NBD1 (Baker et al., 2007) . DSC experiments, which measure the stability of the global structure, were conducted on both truncated and non-truncated NBD1. Truncated NBD1 has an apparent stability improvement of 7.78C relative to the non-truncated NBD1 with solubilizing mutations. Whether this is an improvement of the stability of the folded protein or a reduction in the protein's tendency to aggregate is under investigation.
Reports of NBD1 affinity for ATP range from 2.2 mM (Yike et al., 1996) to 5 mM (Logan et al., 1994; Lu and Pedersen, 2000; Pereira et al., 2007) . The SPR measurements reported here yield an ATP affinity of 2.4 mM for the nontruncated construct. This result is consistent with the highest affinity reported (Yike et al., 1996) , but contrasts with the 148 mM affinity reported for mouse NBD1 with the same domain boundaries using a different method (Lewis et al., 2004) . The truncated NBD1 showed consistently higher affinity (3 -15-fold) for the various nucleotides, perhaps due to removal of the RI which could change the character of the ATP binding site, as indicated in the mouse NBD1 structure (Lewis et al., 2004) . The low micromolar ATP affinity for the non-truncated NBD1 and the submicromolar affinity observed for the truncated NBD1 are confirmed by fits of DSC data for the same constructs in solution (C.G. Brouillette, unpublished results).
Reports of ATP hydrolysis by NBD1 indicate a similarly wide range of activities (Hanrahan et al., 2003; Lewis et al., 2004; Cheung et al., 2008) . As was reported for mouse NBD1 constructs, we were unable to detect hydrolytic activity for the truncated human NBD1s using a coupled assay (data not shown). We suspect that the reported activities vary widely due to their use of poorly behaved NBD1 proteins and the presence of contaminants.
Truncated NBD1 yields structures of wild-type NBD1 as both a monomer and a head-to-tail homodimer, and as a homodimer with the DF508 mutation. Having removed the elements that could interfere with dimerization, it is perhaps not surprising that it crystallizes as a homodimer. The homodimer mimics the biological NBD1:NBD2 heterodimer (Gadsby et al., 2006) . Therefore, aspects of the observed association contribute to an understanding of the heterodimer (Procko et al., 2006) . First, the NBD1:ATP interactions at the Walker A and signature half-sites likely resemble those found in full-length CFTR. The interactions at the signature half-site are of particular interest since they had been inferred and modeled for NBD1 but never observed. Upon binding ATP at the signature site, the presignature loop, residues 542-547 (including Thr547) at the end of the structurally diverse region (Oswald et al., 2006) , adopts an ATP compatible conformation in the homodimer structure. In previously reported monomer structures, this loop is either disordered or exhibits alternate conformations which would clash with a bound ATP molecule. Since this presignature loop interacts with the ICLs in the Sav1866 structure, its conformational changes could be a mechanism of TMD:NBD communication in CFTR (Linton and Higgins, 2007) . The several structures of TAP1 NBD show a similar variability in the presignature loop suggesting that the presignature loop might contribute to TMD:NBD communication in that protein as well (Procko et al., 2006) .
Obtaining a complex of NBD1 and NBD2 was one of the original goals of this work. Initial attempts to detect NBD1:NBD2 association by size exclusion chromatography, SPR and crystallography have so far been negative, yielding no evidence of binding nor complex crystals. While disappointing, this result is not unique. Several groups have reported difficulties in observing dimers of homodimeric and heterodimeric NBDs (Karpowich et al., 2001; Smith et al., 2002; Ramaen et al., 2005; Procko et al., 2006) . Nevertheless an NBD1:NBD2 head-to-tail dimer might eventually be observed crystallographically just as the NBD1 homodimer has been (Yike et al., 1996) .
The results reported herein provide important insights into NBD1 structure and function. They show that the conformation of monomeric NBD1 is largely preformed for dimer association. Upon formation of an NBD1 dimer, equivalent to dimers obtained for other homodimeric NBDs, there is no movement of subdomains, nor of the Walker A or signature regions. The only change upon dimerization is that residues 542-547, the pre-signature loop, become fixed, most likely by the packing of Thr547 against the adenine base. As has been reported, the structural consequences of the DF508 mutation are localized to the site of mutation. A minimal definition of NBD1 excludes the insert and extension, neither of which is necessary to the NBD fold, stability or nucleotide binding. In fact, truncated (minimal) NBD1 displays improved solubility, stability and nucleotide binding and will be an important tool for further studies of NBD1 and the role of the DF508 mutation in Cystic Fibrosis.
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